
Baxalta has signed a deal with Symphogen potentially worth as much as €1.4 billion, under which the companies will develop …

Pfizer, Merck and Syndax Pharmaceuticals have announced a collaboration to test avelumab, in combination with Syndax’s entinostat, in patients with …

The All Wales Medicines Strategy Group has recommended Merck’s Erbitux in combination with chemotherapy for restricted use in the NHS …

Novartis says results from two Phase III studies for Cosentyx in ankylosing spondylitis (AS) showing significant clinical improvements versus placebo.Results …

Dr Bernhard Kirschbaum, 57, has been added as a non-executive director at RedX Pharma with immediate effect. Kirschbaum is a …

The deal may have failed to get over the line in 2015, but reports suggest the mega merger is to …

The pharma industry has been singled out for its strong performance in 2015, in a report which says manufacturing in …
Takeda and Teva have detailed plans for a new joint venture to create a new company to market off-patent generic …

KaloBios has filed for bankruptcy in the wake of chief executive Martin Shkreli’s arrest on securities fraud charges last month …

Merry Christmas and a happy new year from all at Pharmafocus!We will be back on Monday 4 January with all …

The World Health Organisation (WHO) has accepted MSD’s application for the company’s investigational Ebola vaccine, V920 (Zebov), to be reviewed …

Johnson & Johnson and Purdue Pharma have settled separate lawsuits with the US state of Kentucky for a total of …

Boehringer Ingelheim will kick off its pharma investments in 2016 with a half a billion Euro outlay and plans to …

Increasing pressures from customers, drug manufacturers and regulators to convert prescription medications to over-the-counter (OTC) non-prescription status is driving growth …

What will be the key industry trends in 2016?Pricing pressures

Celgene has settled its litigation with Natco Pharma, over the patents for Revlimid, opening the door to increased generic competition …

The US FDA has approved AstraZeneca’s Zurampic to treat high levels of uric acid in the blood. The drug is …

NICE has published final guidance recommending Velcade (bortezomib) as a treatment for previously untreated mantle cell lymphoma (MCL). In the …

Peter Culpepper, chief operating officer at Provectus Biopharmaceuticals, explains the secrets of Rose Bengal, which has impressed in clinical trials …

GSK is charging up to four times more for its recently approved asthma drug Nucala than is justified by cost-effectiveness …